ArticleJournal of inflammation research2026
NHWD-870, a Potent BET Inhibitor, Ameliorated Endotoxemia-Induced Hepatic Inflammation via Suppression of BRD4-STAT1 Signaling and Macrophage M1 Polarization.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis remains a leading cause of mortality in intensive care units, with endotoxemia-induced hepatic inflammation being a major contributor to multiorgan failure. Bromodomain and extraterminal domain (BET) proteins are key epigenetic regulators of inflammation. While the BET inhibitor JQ1 shows protective effects in sepsis models, its toxicity limits translational application. NHWD-870, a next-generation BET inhibitor with improved potency and safety, has not been evaluated in septic liver injury. Methods: Eight-week-old male C57BL/6 mice were challenged with lipopolysaccharide (LPS) to induce endotoxemia and treated with NHWD-870 1 hour before LPS challenge. Survival rate was assessed and 0.5mg/kg was selected as the optimal dose. Liver injury and inflammation were assessed by histopathology, serum biochemistry, ELISA, RT-qPCR, and immunohistochemistry. In vitro, primary mouse hepatocytes (PMHs) and bone marrow-derived macrophages (BMDMs) were stimulated with LPS to examine NHWD-870 effects on cytokine production and macrophage polarization. Results: NHWD-870 improved survival in lethal LPS challenge and attenuated LPS induced ALT/AST elevations and hepatic inflammatory infiltration. Serum and hepatic IL6, TNFα, and MCP1 were reduced after NHWD-870; IL6 suppression at 12 h exceeded JQ1. NHWD-870 decreased hepatic macrophage and neutrophil infiltration and no obvious histopathological abnormalities were observed in the major organs at the active dose. In vitro, NHWD-870 dose dependently reduced LPS induced cytokine expression in PMH and BMDM and inhibited macrophage M1 polarization (CD86, iNOS). BRD4 and STAT1 expression increased after LPS; NHWD 870 suppressed both. Conclusion: NHWD-870 ameliorates endotoxemia-associated hepatic inflammation and improves survival in mice, at least in part via suppression of BRD4-STAT1 signaling and inhibition of macrophage M1 polarization. Further preclinical development is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.